Related Experiment Video
Updated: Jul 15, 2026
06:49
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
[Renal cell carcinoma in Iceland]
Asgeir Thoroddsen1, Gudmundur Vikar Einarsson, Tómas Gudbjartsson
1Thvagfaeraskurddeild Landspítala.
Laeknabladid
|April 27, 2007
Summary
Renal Cell Carcinoma (RCC), the most common kidney cancer, presents diverse clinical behaviors and rising global incidence. This review focuses on RCC epidemiology and presentation in Iceland, where incidence is notably high.
Area of Science:
- Oncology
- Urology
- Epidemiology
Context:
- Renal Cell Carcinoma (RCC) is the predominant kidney malignancy, characterized by clinical heterogeneity and limited understanding of its etiology and risk factors.
- The global incidence of RCC is increasing, yet mortality-to-incidence ratios remain higher than for other urologic malignancies, indicating a significant adverse prognosis for many patients.
Purpose:
- To review major studies on Renal Cell Carcinoma (RCC).
- To emphasize the epidemiology and clinicopathological presentation of RCC, particularly in Iceland, a country with a higher incidence rate.
Summary:
- RCC exhibits diverse clinical behaviors and rising global incidence, with ongoing advancements in understanding its genetics and biology.
- Therapeutic progress includes immunotherapies, tyrosine kinase inhibitors, and improved surgical techniques, alongside increased incidental detection via imaging.
- Iceland experiences a disproportionately high incidence of RCC, with approximately 30 new cases and 14 deaths annually.
Impact:
- Improved understanding of RCC's genetic and biological underpinnings.
- Development of novel treatments like immunotherapies and targeted agents for advanced RCC.
- Potential for improved patient prognosis through early detection and advanced therapies, with a specific focus on the Icelandic population.
